AU Patent

AU2013205325B2 — Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases

Assigned to University of California San Diego UCSD · Expires 2016-03-24 · 10y expired

What this patent protects

A hydantoin compound useful for the prevention or treatment of hyperproliferative diseases or disorders.

USPTO Abstract

A hydantoin compound useful for the prevention or treatment of hyperproliferative diseases or disorders.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013205325B2
Jurisdiction
AU
Classification
—
Expires
2016-03-24
Drug substance claim
No
Drug product claim
No
Assignee
University of California San Diego UCSD
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.